CD8A and leukemia: That was evidenced by lower leukemia burden, longer mice survival, improved CD8 CAR-T expansion, increased CAR-T infiltration in bone marrow, more effector memory CAR-T cells, fewer effector CAR-T cells, and diminished expression of exhaustion and activation markers (Fig. 2b–h).